HKT TRUST Aktie

 

Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March......

ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing novel, differentiated therapies to address unmet medical needs in cancer, today reported it will release its full year 2025 unaudited results and provide business updates at 7:00 pm Eastern Daylight Time (EDT) on March 25, 2026 / 7:00 am Hong Kong Time (HKT) on March 26, 2026....

Stocks | Potential Upside from Target PricesAlibaba (BABA.US) | 17.8%CHALCO (601600.SH) | +20.7%CATL (300750.SZ) | 33.3%DUALITYBIO-B (09606.HK) | 41.8%ESPRESSIF (688018.SH)| 30.7%HKEX (00388.HK) | 22%HKT-SS (06823.HK) | 7.1%NARI (600406.SH) | 0.9%PING AN (02318.HK) | 22.6%INOVANCE TECH (300124.SZ) | 25.7%SINOMA SCI & TECH (0......

– Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026 – Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE) – Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026 Conference call and webcast today, February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2025, along with recent product highlights and corporate updates. “20...

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

- Company to host conference call and webcast on February 26, 2026, at 8:00 a.m. ET (9:00 p.m. HKT)SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2025 financial results and provide recent corporate updates on February 26, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): https://edge.media-server.com/mmc/p/ftt8dzjp Registration link for dial-in: https://register-conf.media-server.com/register/BI3888301d591947ae8d0ccb041164c8e6 All participants must use the link provided above to complete the online registration process in advance of th...

The Group has made advance preparations for Hong Kong's accelerated pursuit of sci-tech self-reliance and self-strengthening at higher levels, Susanna Hui, Managing Director of HKT-SS (06823.HK), said. The Group recently established a new AI facility and R&D center in the Lok Ma Chau Loop, serving the Northern Metropolis......

HKT-SS (06823.HK) and PCCW (00008.HK) issued a joint announcement saying that, on 7 February 2026, HKT-SS received an offer from a company solely controlled by China Merchants Capital Holdings (CM Capital), CM Silk Road Capital Management Limited, to acquire from PCCW a further 9% equity interest in the Target, Regional Link Tel......

HKT-SS (06823.HK) has announced its results for the year ending December 2025. Profit attributable to holders of Share Stapled Units increased by 4.3% YoY to HKD5.286 billion, with EPS standing at HK69.76 cents.The final distribution per Share Stapled Unit was HK47.97 cents, compared to the HK45.88 cents distributed in the same ......

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT)....

HKT-SS (06823.HK) announced today (5th) a collaboration with YuShu Technology, a renowned Chinese Mainland robotics company and one of Hangzhou's "Six Little Dragons".The two companies will promote the adoption of physical AI and related innovative technologies among local and global enterprises, accelerating their......

Morgan Stanley released a China market strategy report, providing a focus list of Hong Kong and Chinese stocks:Stocks | Potential Upside from Target PricesAlibaba (BABA.US) | 8.8%Yangtze Power (600900.SH) | 29.7%CATL (300750.SZ) | 40.3%DUALITYBIO-B (09606.HK) | 38.9%Espressif (688018.SH) | 25.1%HKEX (00388.HK) | 17.7%HKT-SS (068......

Stock | Potential Upside to Target PriceAlibaba (BABA.US) | 16.5%YANGTZE POWER (600900.SH) | 27.6%CONTEMPORARY AMPEREX (300750.SZ) | 32.7%DUALITYBIO-B (09606.HK) | 39.3%ESPRESSIF (688018.SH) | 26.9%HKEX (00388.HK) | 19.5%HKT-SS (06823.HK) | 10.7%NARI (600406.SH) | 12.3%PING AN (02318.HK) | 26.8%INOVANCE TECH (300124.SZ) | 22.5%S......

Stock | Investment Rating | Potential Upside to Target PriceAlibaba (BABA.US) | Overweight | 27.1%YANGTZE POWER (600900.SH) | Overweight | 24.3%CONTEMPORARY AMPEREX (300750.SZ) | Overweight | 31.3%DUALITYBIO-B (09606.HK) | Overweight | 42.7%ESPRESSIF (688018.SH) | Overweight | 31.5%HKEX (00388.HK) | Overweight | 23.6%HKT-SS (068......

Morgan Stanley released a China market strategy report, presenting its focus list for H-shares, Chinese ADRs, and A-shares:Stocks | Potential Upside from TPsAlibaba (BABA.US) | 26.7%Yangtze Power (600900.SH) | 21.6%CATL (300750.SZ) | 26.6%DUALITYBIO-B (09606.HK) | 60.5%ESPRESSIF (688018.SH) | 40.4%HKEX (00388.HK) | 16.1%HKT-SS (......

The US Federal Communications Commission (FCC) recently announced its intention to revoke the business operation license of HKT-SS (06823.HK), a subsidiary of PCCW (00008.HK), in the US. The FCC also issued a "Order to Show Cause (OSC)", requiring HKT to respond within 30 days with reasons against the proposed action. ......

Regarding the US Federal Communication Commission (FCC)'s proposal to revoke the license of HKT-SS (06823.HK)'s subsidiary to provide telecommunications services in the US, UBS believed that the potential ban will have limited impact on the Company's earnings due to its small exposure to the US market. The US market ......

The US Federal Communications Commission plans to revoke HKT-SS' (06823.HK) operating license in the US on the grounds of national security concerns.When responding to media questions, a spokesperson for the Hong Kong government expressed strong dissatisfaction with the US overgeneralizing the national security concept.The s......

The US Federal Communications Commission (FCC) announced its intent to revoke the license of HKT-SS (06823.HK), a subsidiary of PCCW (00008.HK), to provide telecommunications services in the US. The FCC has issued an Order to Show Cause requesting HKT-SS to provide justification why the revocation process should not proceed.HKT-......

The US Federal Communications Commission (FCC) intended to revoke the operating license of HKT International, a wholly-owned subsidiary of HKT-SS (06823.HK), in the US due to its ties with China Unicom Americas. If the revocation process is enacted, the impact on HKT-SS' fundamentals should be manageable, as its internationa......